Peiyi Zhang
University of Florida
H-index: 13
North America-United States
Top articles of Peiyi Zhang
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Development and crystal structures of a potent second-generation dual degrader of BCL-2 and BCL-xL | Nature communications | Digant Nayak Dongwen Lv Yaxia Yuan Peiyi Zhang Wanyi Hu | 2024/3/29 |
Rational targeting of BCL-xL and/or mTOR enhance the efficacy of KRASG12D inhibitor in pancreatic cancer | Cancer Research | Sajid Khan Lin Cao Vignesh Vudhata Yang Yang Peiyi Zhang | 2024/3/22 |
PROTAC-mediated dual degradation of BCL-xL and BCL-2 is a highly effective therapeutic strategy in small-cell lung cancer | Cells | Sajid Khan Lin Cao Janet Wiegand Peiyi Zhang Maria Zajac-Kaye | 2024/3/17 |
Enriched Signalling Pathways in Venetoclax-Relapsed Chronic Lymphocytic Leukemia (CLL) Cells and Targeting Using a Protac-Based Bcl-2/Bcl-Xl Degrader | Blood | Daisy Diaz Rohena Arnau Peris Cuesta Bailey Slawin Janani Ravikrishnan Chaomei Liu | 2023/11/28 |
Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cells | Haematologica | Yannan Jia Lina Han Cassandra L Ramage Zhe Wang Connie C Weng | 2023/10/10 |
Abstract B009: A liver-tropic BCL-xL PROTAC effectively clears senescent hepatocytes and prevents NASH-driven HCC in mice | Cancer Research | Yang Yang Natacha Jn-Simon Wanyi Hu Peiyi Zhang Guangrong Zheng | 2023/1/15 |
Co-targeting BCL-XL and MCL-1 with DT2216 and AZD8055 synergistically inhibit small-cell lung cancer growth without causing on-target toxicities in mice | Cell Death Discovery | Sajid Khan Patrick Kellish Nick Connis Dinesh Thummuri Janet Wiegand | 2023/1/2 |
Targeting venetoclax resistant CLL using a protac-based BCL-2/BCL-XL degrader | Blood | Daisy Diaz Rohena Bailey Slawin Janani Ravikrishnan Chaomei Liu Wanyi Hu | 2022/11/15 |
Therapeutic agents and methods of treatment | 2023/10/26 | ||
THERAPEUTICS AND TREATMENT METHODS | 2022/10/26 | ||
BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers | Journal of Hematology & Oncology | Sajid Khan Janet Wiegand Peiyi Zhang Wanyi Hu Dinesh Thummuri | 2022/3/9 |
Overcoming Gemcitabine Resistance in Pancreatic Cancer Using the BCL-XL–Specific Degrader DT2216 | Molecular cancer therapeutics | Dinesh Thummuri Sajid Khan Patrick W Underwood Peiyi Zhang Janet Wiegand | 2022/1/1 |
Targeting BCL-XL in fibrolamellar hepatocellular carcinoma | JCI insight | Bassem Shebl Denise Ng Gadi Lalazar Carly Rosemore Tova M Finkelstein | 2022/9/9 |
Patent landscape of inhibitors and PROTACs of the anti-apoptotic BCL-2 family proteins | Pratik Pal Peiyi Zhang Saikat K Poddar Guangrong Zheng | 2022/9/2 | |
A BCL-XL PROTAC degrader DT2216 synergizes with KRASG12C inhibitors for effectively treating KRASG12C-mutated cancers | Cancer Research | Sajid Khan Janet Wiegand Peiyi Zhang Wanyi Hu Dinesh Thummuri | 2022/6/15 |
Dual BCL-XL/2 Protac 753B Not Only Potently Induces Apoptosis in Venetoclax-Resistant Primary AML Cells but Also Effectively Eliminates Chemotherapy-Induced Senescent AML Cells | Blood | Yannan Jia Lina Han Cassandra L Ramage Connie C Weng Lei Yang | 2022/11/15 |
Proteolysis-targeting chimera against BCL-XL destroys tumor-infiltrating regulatory T cells | Nature communications | Ryan Kolb Umasankar De Sajid Khan Yuewan Luo Myung-Chul Kim | 2021/2/24 |
Targeting BCL-XL and BCL-2 by protac 753B effectively eliminates AML cells and enhances efficacy of chemotherapy by targeting senescent cells | Blood | Yannan Jia Qi Zhang Weiguo Zhang Michael Andreeff Nitin Jain | 2021/11/23 |
Concise Synthesis of (S)-δ-CEHC, a Metabolite of Vitamin E | ACS omega | Matthew Burke Pratik Pal Peiyi Zhang Xuan Zhang Guangrong Zheng | 2021/2/2 |
Targeting Venetoclax-Resistant CLL By Bcl-XL Degradation | Blood | Daisy Diaz Rohena Janani Ravikrishnan Chaomei Liu Guangrong Zheng Daohong Zhou | 2021/11/23 |
Co-Authors
